Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

Market Cap	21.07B -6.4%
Revenue (ttm)	6.01B +2.7%
Net Income	1.07B -8.9%
EPS	1.06 -9.3%
Shares Out	1.02B
PE Ratio	19.55
Forward PE	16.33
Dividend	0.40 (1.94%)
Ex-Dividend Date	May 14, 2025

Volume	4,288,575
Average Volume	13,178,731
Open	21.02
Previous Close	20.74
Day's Range	20.40 - 21.02
52-Week Range	20.39 - 29.30
Beta	-0.16
RSI	34.50
Earnings Date	Jul 30, 2026

About SHE:002262

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 6,003
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002262

Financial Performance

In 2025, SHE:002262's revenue was 5.91 billion, an increase of 3.75% compared to the previous year's 5.70 billion. Earnings were 1.06 billion, a decrease of -7.54%.